Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This was the stock's second consecutive day of losses.

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other biotech stocks. As we have mentioned in our article, “10 Best ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 13.03% on an annualized basis producing an average annual return of 21.14%. Currently, Vertex Pharmaceuticals has ...

India's fourth largest pharma company is taking a big leap with a costly acquisition which many think needs to be watched. But Ramesh C Juneja and Rajeev Juneja, who cofounded Mankind, think the ...

BigEndian Semiconductors, a fabless-semiconductor design startup, raised $3 million in a funding round led by Vertex Ventures SEA & India. The funds will be used to expand the company’s engineering ...

Recursion Pharmaceuticals Inc RXRX shares are trading lower. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM).

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...